EMERGENT BIOSOLUTIONS INC. (EBS)

5.91 -0.51% (-0.03)

Over 5Y: -90.8%

2026-08-28
20 40 60
2021 2022 2023 2024 2025 2026

Financials Quarterly

Q3 '25 — Revenue: 231.1M Q3 '25 — Operating Cash Flow: -2.3M Q3 '25 — Free Cash Flow: -5.7M Q3 '25 — Net Income: 51.2M Q4 '25 — Revenue: 148.7M Q4 '25 — Operating Cash Flow: 77.7M Q4 '25 — Free Cash Flow: 73.8M Q4 '25 — Net Income: -54.6M Q1 '26 — Revenue: 156.1M Q1 '26 — Operating Cash Flow: -33.8M Q1 '26 — Free Cash Flow: -36.2M Q1 '26 — Net Income: 6.8M Q2 '26 — Revenue: 234.3M Q2 '26 — Operating Cash Flow: 56.1M Q2 '26 — Free Cash Flow: 54M Q2 '26 — Net Income: -180.2M -180M -90M 0 90M 180M 270M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

4.4
Oper. margin 13.0%
OE margin 8.7%
ROIC 10.0%
Accruals -24.6%
Gross margin 55.9%
FCF margin 11.2%
OCF margin 12.7%
ROCE 10.1%
OCF / EBIT 0.98×
Profit margin -23.0%
ROA -15.8%
ROE -51.8%

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.6
RPO / sales 0.35×
RPO growth -9.5%
Segment HHI —

4 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

5.5
ND/EBITDA —
Quick ratio 3.0×
F-score 7.0 pts
Cash / Debt 0.24×
Debt payback 5.2 yr
Debt / Eq 1.7×
Cash runway —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.7
Sales CAGR 4Y -19.6%
Sales/sh Y/Y -15.5%
Sales Q/Q +66.3%
EPS CAGR 4Y -30.8%
EPS Y/Y -218.5%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.